Sheldon Berger

557 total citations
24 papers, 418 citations indexed

About

Sheldon Berger is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Sheldon Berger has authored 24 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in Sheldon Berger's work include Pancreatic function and diabetes (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Muscle metabolism and nutrition (3 papers). Sheldon Berger is often cited by papers focused on Pancreatic function and diabetes (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Muscle metabolism and nutrition (3 papers). Sheldon Berger collaborates with scholars based in United States, France and Germany. Sheldon Berger's co-authors include Robert Metz, Mary E. Mako, Stephen P. Thomson, Vivian Fonseca, David S.H. Bell, J. P. Raufman, Robert E. Ratner, P. Raskin, Vincent Woo and Lois Jovanovič and has published in prestigious journals such as Science, New England Journal of Medicine and JAMA.

In The Last Decade

Sheldon Berger

24 papers receiving 360 citations

Peers

Sheldon Berger
T Matsuoka Japan
J. R. W. Dykes United Kingdom
David B. Jacobs United States
C. D. N. Toseland United Kingdom
Elisabeth Hjøllund Denmark
M. Traversa Italy
C. C. Donner United States
Alberti Kg United Kingdom
M Cerri Italy
H. Yki-J�rvinen Finland
T Matsuoka Japan
Sheldon Berger
Citations per year, relative to Sheldon Berger Sheldon Berger (= 1×) peers T Matsuoka

Countries citing papers authored by Sheldon Berger

Since Specialization
Citations

This map shows the geographic impact of Sheldon Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheldon Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheldon Berger more than expected).

Fields of papers citing papers by Sheldon Berger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheldon Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheldon Berger. The network helps show where Sheldon Berger may publish in the future.

Co-authorship network of co-authors of Sheldon Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Sheldon Berger. A scholar is included among the top collaborators of Sheldon Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheldon Berger. Sheldon Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pfützner, Andreas, Sheldon Berger, & G A Spinas. (2000). [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus].. PubMed. 130(48). 1854–61. 6 indexed citations
3.
LaCreta, Frank, et al.. (2000). Effect of Multiple‐Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin‐Dependent Diabetes Mellitus Maintained with Diet and Exercise. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(6P2). 76S–86S. 47 indexed citations
4.
Raskin, P., et al.. (2000). Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.. Diabetes Care. 23(7). 979–983. 42 indexed citations
5.
Berger, Sheldon, et al.. (1998). General pharmacology of S 15261, a new concept for treatment of diabetes.. PubMed. 48(7). 734–44. 6 indexed citations
6.
Berger, Sheldon, et al.. (1998). ChemInform Abstract: General Pharmacology of S 15261 (I), a New Concept for Treatment of Diabetes.. ChemInform. 29(44). 1 indexed citations
7.
Espinal, J., et al.. (1995). S15261 antagonises amylin‐induced impaired glucose tolerance. FEBS Letters. 368(1). 36–38. 3 indexed citations
8.
Berger, Sheldon, et al.. (1979). Active cell aggregation by immature rat Sertoli cells in primary culture: A role for cell surface glycoproteins. Journal of Cellular Physiology. 99(2). 175–182. 7 indexed citations
9.
Colwell, Arthur R., L Zuckerman, & Sheldon Berger. (1970). Pancreatic Insulin Secretion Following Intrapancreatic Infusion of Amino Acid. Diabetes. 19(4). 217–227. 6 indexed citations
10.
Metz, Robert, Sheldon Berger, & Mary E. Mako. (1969). Potentiation of the Plasma Insulin Response to Glucose by Prior Administration of Alcohol: An Apparent Islet-Priming Effect. Diabetes. 18(8). 517–522. 75 indexed citations
11.
Green, Orville C. & Sheldon Berger. (1968). THE CLINICAL USE OF DIAZOXIDE IN LEUCINE‐SENSITIVE HYPOGLYCEMIA*. Annals of the New York Academy of Sciences. 150(2). 356–366. 5 indexed citations
12.
Cohn, Clarence, et al.. (1968). Relationship between Meal Size and Frequency and Plasma Insulin Response in Man. Diabetes. 17(2). 72–75. 14 indexed citations
13.
Metz, Robert, et al.. (1968). Preservation of insulin and liver glycogen stores during very long fasts.. PubMed. 71(4). 573–81. 4 indexed citations
14.
Berger, Sheldon, et al.. (1966). Mechanism of the Cortisone-Modified Glucose Tolerance Test. New England Journal of Medicine. 274(26). 1460–1464. 10 indexed citations
15.
Berger, Sheldon, et al.. (1966). Insulin Response to Ingested Protein in Diabetes. Diabetes. 15(5). 303–306. 63 indexed citations
16.
Berger, Sheldon, et al.. (1962). Circulating Iodoprotein in Two Patients with Autonomous Thyroid Nodules*. The Journal of Clinical Endocrinology & Metabolism. 22(1). 1–7. 9 indexed citations
17.
Levine, Rachmiel & Sheldon Berger. (1960). Orally active hypoglycemic substances and the rationale of their use. Clinical Pharmacology & Therapeutics. 1(2). 227–246. 2 indexed citations
18.
Foà, Piero P., et al.. (1953). Extraction of the Hyperglycemic Factor (HGF) of the Pancreas with Liquid Ammonia. Science. 117(3030). 82–84. 4 indexed citations
19.
Berger, Sheldon, et al.. (1952). Effects of the Hyperglycemic-Glycogenolytic Factor (HGF), Epinephrine and Insulin in Normal and Depancreatized Dogs.. Experimental Biology and Medicine. 80(4). 635–639. 8 indexed citations
20.
Foà, Piero P., et al.. (1952). Secretion of the Hyperglycemic-Glycogenolytic Factor in Normal Dogs. American Journal of Physiology-Legacy Content. 171(1). 32–36. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T Matsuoka Breakdown of academic impact, for papers by J. R. W. Dykes Breakdown of academic impact, for papers by David B. Jacobs Breakdown of academic impact, for papers by C. D. N. Toseland Breakdown of academic impact, for papers by Elisabeth Hjøllund Breakdown of academic impact, for papers by M. Traversa Breakdown of academic impact, for papers by C. C. Donner Breakdown of academic impact, for papers by Alberti Kg Breakdown of academic impact, for papers by M Cerri Breakdown of academic impact, for papers by H. Yki-J�rvinen
Rankless by CCL
2026